Last reviewed · How we verify
GSK249320
At a glance
| Generic name | GSK249320 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Constipation
- Vomiting
- Hypokalaemia
- Glucose tolerance impaired
- Urinary tract infection
- Insomnia
- Restlessness
- Atrial fibrillation
- Atrial flutter
- Atrioventricular block complete
- Bradycardia
- Headache
Key clinical trials
- Safety Escalating Repeat IV, in Stroke Patients (PHASE2)
- Proof of Concept (POC) in Patients With Ischaemic Stroke (PHASE2)
- Anti-MAG First Administration to Human (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK249320 CI brief — competitive landscape report
- GSK249320 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI